Suvretta Capital Management, LLC bought $539k of BNTC
director, owner at Benitec Biopharma Inc.. 46,141 shares at an average of $11.68, traded Dec 18, 2025, filed Dec 22, 2025.
Score components
- +15RoleDirector
- +19Trade size$539k at market
- -5Relative to holdingsUnder 1% of holdings (0.5%)
- +8Price context32% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000899140-25-001459, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 18, 2025 | POpen-market purchase Common stock, par value $0.0001 per shareindirect: See footnotes | +8,700 | $11.24 | $98k | 9,546,875 | Dec 22, 2025 |
| Dec 18, 2025 | POpen-market purchase Common stock, par value $0.0001 per shareindirect: See footnotes | +1,515 | $11.24 | $17k | 1,821,327 | Dec 22, 2025 |
| Dec 19, 2025 | POpen-market purchase Common stock, par value $0.0001 per shareindirect: See footnotes | +13,950 | $11.48 | $160k | 9,560,825 | Dec 22, 2025 |
| Dec 19, 2025 | POpen-market purchase Common stock, par value $0.0001 per shareindirect: See footnotes | +2,434 | $11.48 | $28k | 1,823,761 | Dec 22, 2025 |
| Dec 22, 2025 | POpen-market purchase Common stock, par value $0.0001 per shareindirect: See footnotes | +16,650 | $12.08 | $201k | 9,577,475 | Dec 22, 2025 |
| Dec 22, 2025 | POpen-market purchase Common stock, par value $0.0001 per shareindirect: See footnotes | +2,892 | $12.08 | $35k | 1,826,653 | Dec 22, 2025 |
Related signals
Other insiders at Benitec Biopharma Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 49Moderate | BNTCbuy Benitec Biopharma Inc. | Suvretta Capital Management, LLC director, owner | $1.9M 144,223 shares | +2% | |
| 47Moderate | BNTCbuy Benitec Biopharma Inc. | Suvretta Capital Management, LLC director, owner | $20M 1,481,481 shares | +17% | |
| 31Weak | BNTCbuy Benitec Biopharma Inc. | Suvretta Capital Management, LLC director, owner | $212k 16,497 shares | +0% | |
| 47Moderate | BNTCbuy Benitec Biopharma Inc. | Suvretta Capital Management, LLC director, owner | $12M 900,000 shares | +11% | |
| 33Weak | BNTCbuy Benitec Biopharma Inc. | Suvretta Capital Management, LLC director, owner | $527k 47,520 shares | +1% | |
| 31Weak | BNTCbuy Benitec Biopharma Inc. | Suvretta Capital Management, LLC director, owner | $403k 42,000 shares | +1% | |
| 26Weak | BNTCbuy Benitec Biopharma Inc. | Suvretta Capital Management, LLC director, owner | $417k 41,436 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.